title: Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus.
abstract: The effector functions of specific CD8 T cells are crucial in mediating influenza heterologous protection. However, new approaches for influenza vaccines that can trigger effective CD8 T cell responses have not been extensively explored. We report here the generation of single-cycle infectious influenza virus that lacks a functional hemagglutinin (HA) gene on an X31 genetic background and demonstrate its potential for triggering protective CD8 T cell immunity against heterologous influenza virus challenge. In vitro, X31-sciIV can infect MDCK cells, but infectious virions are not produced unless HA is transcomplemented. In vivo, intranasal immunization with X31-sciIV does not cause any clinical symptoms in mice but generates influenza-specific CD8 T cells in lymphoid (mediastinal lymph nodes and spleen) and nonlymphoid tissues, including lung and bronchoalveolar lavage fluid, as measured by H2-Db NP366 and PA224 tetramer staining. In addition, a significant proportion of X31-sciIV-induced antigen-specific respiratory CD8 T cells expressed VLA-1, a marker that is associated with heterologous influenza protection. Further, these influenza-specific CD8 T cells produce antiviral cytokines when stimulated with NP366 and PA224 peptides, indicating that CD8 T cells triggered by X31-sciIV are functional. When challenged with a lethal dose of heterologous PR8 virus, X31-sciIV-primed mice were fully protected from death. However, when CD8 T cells were depleted after priming or before priming, mice could not effectively control virus replication or survive the lethal challenge, indicating that X31-sciIV-induced memory CD8 T cells mediate the heterologous protection. Thus, our results demonstrate the potential for sciIV as a CD8 T cell-inducing vaccine. Importance: One of the challenges for influenza prevention is the existence of multiple influenza virus subtypes and variants and the fact that new strains can emerge yearly. Numerous studies have indicated that the effector functions of specific CD8 T cells are crucial in mediating influenza heterologous protection. However, influenza vaccines that can trigger effective CD8 T cell responses for heterologous protection have not been developed. We report here the generation of an X31 (H3N2) virus-derived single-cycle infectious influenza virus, X31-sciIV. A one-dose immunization with X31-sciIV is capable of inducing functional influenza virus-specific CD8 T cells that can be recruited into respiratory tissues and provide protection against lethal heterologous challenge. Without these cells, protection against lethal challenge was essentially lost. Our data indicate that an influenza vaccine that primarily relies on CD8 T cells for protection could be developed.
authors.affiliation: Center for Infectious Diseases and Vaccine Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA jackguo1234@yahoo.com david_topham@urmc.rochester.edu.
authors.forename: Hailong
authors.initials: H
authors.lastname: Guo
authors.affiliation: Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.
authors.forename: Steven F
authors.initials: SF
authors.lastname: Baker
authors.affiliation: Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.
authors.forename: Luis
authors.initials: L
authors.lastname: Martínez-Sobrido
authors.affiliation: David H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, University of Rochester, Rochester, New York, USA jackguo1234@yahoo.com david_topham@urmc.rochester.edu.
authors.forename: David J
authors.initials: DJ
authors.lastname: Topham
mesh_terms: D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D004285:Dogs; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D057809:HEK293 Cells; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000032:analysis; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D008212:Lymphocyte Depletion; D051379:Mice; D008810:Mice, Inbred C57BL
chemical_list: D019267:Hemagglutinin Glycoproteins, Influenza Virus
references.citation: J Immunol. 2007 Apr 1;178(7):4506-16
references.pmid: 17372009
references.citation: Immunology. 1999 Aug;97(4):679-85
references.pmid: 10457223
references.citation: J Virol. 2008 Jun;82(11):5161-6
references.pmid: 18353950
references.citation: J Virol. 1998 Aug;72(8):6437-41
references.pmid: 9658085
references.citation: J Virol. 2001 Jan;75(1):83-9
references.pmid: 11119576
references.citation: Microbiol Rev. 1992 Mar;56(1):152-79
references.pmid: 1579108
references.citation: PLoS Pathog. 2009 Jan;5(1):e1000272
references.pmid: 19165322
references.citation: Vaccine. 2008 May 23;26(22):2762-71
references.pmid: 18423946
references.citation: J Virol. 2009 Jun;83(11):5947-50
references.pmid: 19321619
references.citation: J Virol. 2004 Dec;78(23):13037-45
references.pmid: 15542655
references.citation: J Immunol. 1997 Dec 1;159(11):5197-200
references.pmid: 9548456
references.citation: PLoS Pathog. 2011 Oct;7(10):e1002295
references.pmid: 21998590
references.citation: Nature. 1977 May 26;267(5609):354-6
references.pmid: 194164
references.citation: J Exp Med. 1984 Feb 1;159(2):365-77
references.pmid: 6198430
references.citation: Immunity. 2004 Feb;20(2):167-79
references.pmid: 14975239
references.citation: Microbiol Immunol. 2011 Jan;55(1):19-27
references.pmid: 21175770
references.citation: Vaccine. 2007 Jun 28;25(27):5086-96
references.pmid: 17544181
references.citation: Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1965-73
references.pmid: 11779399
references.citation: Nat Med. 2010 Mar;16(3):339-45
references.pmid: 20139992
references.citation: MMWR Recomm Rep. 2017 Aug 25;66(2):1-20
references.pmid: 28841201
references.citation: Bull World Health Organ. 1969;41(3):643-5
references.pmid: 5309489
references.citation: Immunol Cell Biol. 2009 May-Jun;87(4):300-8
references.pmid: 19308073
references.citation: Immunol Rev. 2006 Jun;211:133-45
references.pmid: 16824123
references.citation: Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4309-14
references.pmid: 10725408
references.citation: Pharmacol Ther. 2008 Nov;120(2):186-96
references.pmid: 18801385
references.citation: Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20365-70
references.pmid: 19918065
references.citation: J Virol. 2010 Mar;84(6):2820-31
references.pmid: 20053743
references.citation: PLoS One. 2012;7(9):e46166
references.pmid: 23029425
references.citation: J Immunol. 1994 Feb 15;152(4):1653-61
references.pmid: 8120375
references.citation: Nature. 1978 May 18;273(5659):238-9
references.pmid: 306072
references.citation: PLoS Pathog. 2011 Nov;7(11):e1002381
references.pmid: 22102819
references.citation: J Virol. 2002 May;76(10):4886-90
references.pmid: 11967305
references.citation: Vaccine. 2008 Sep 12;26 Suppl 4:D49-53
references.pmid: 19230160
references.citation: J Vis Exp. 2010 Aug 03;(42):
references.pmid: 20729804
references.citation: J Virol. 2010 Feb;84(4):2157-63
references.pmid: 19939917
references.citation: Virology. 1998 Dec 20;252(2):324-30
references.pmid: 9878611
references.citation: Viruses. 2010;2(8):1530-1563
references.pmid: 21442033
references.citation: J Virol. 2007 Sep;81(18):9727-36
references.pmid: 17634232
references.citation: Lancet Infect Dis. 2012 Jan;12(1):36-44
references.pmid: 22032844
references.citation: J Virol. 2011 Jan;85(1):448-55
references.pmid: 20980523
references.citation: Virology. 2006 Jan 5;344(1):230-9
references.pmid: 16364753
references.citation: J Gen Virol. 2000 Nov;81(Pt 11):2689-2696
references.pmid: 11038381
references.citation: J Virol. 2011 Feb;85(4):1684-95
references.pmid: 21123370
references.citation: Annu Rev Immunol. 2000;18:275-308
references.pmid: 10837060
references.citation: Vaccine. 2012 Jun 22;30(30):4480-9
references.pmid: 22575164
references.citation: Proc Natl Acad Sci U S A. 1985 Mar;82(6):1785-9
references.pmid: 3872457
references.citation: J Virol. 2000 Apr;74(8):3486-93
references.pmid: 10729122
references.citation: Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1049-54
references.pmid: 24395804
references.citation: Cell. 1986 Mar 28;44(6):959-68
references.pmid: 2420472
references.citation: J Virol. 2013 Aug;87(15):8591-605
references.pmid: 23720727